RYUHX
Price
$19.45
Change
-$0.21 (-1.07%)
Updated
Dec 24 closing price
USPIX
Price
$24.82
Change
-$0.69 (-2.70%)
Updated
Dec 24 closing price
Ad is loading...

RYUHX vs USPIX

Header iconRYUHX vs USPIX Comparison
Open Charts RYUHX vs USPIXBanner chart's image
Rydex Inverse S&P 500® Strategy H
Price$19.45
Change-$0.21 (-1.07%)
VolumeN/A
CapitalizationN/A
ProFunds UltraShort NASDAQ-100 I
Price$24.82
Change-$0.69 (-2.70%)
VolumeN/A
CapitalizationN/A
RYUHX vs USPIX Comparison Chart
Loading...
View a ticker or compare two or three
VS
RYUHX vs. USPIX commentary
Dec 26, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RYUHX is a Hold and USPIX is a Hold.

Ad is loading...
FUNDAMENTALS
Fundamentals
RYUHX has more cash in the bank: 31.7M vs. USPIX (9.32M). USPIX pays higher dividends than RYUHX: USPIX (6.90) vs RYUHX (3.32). RYUHX was incepted earlier than USPIX: RYUHX (10 years) vs USPIX (27 years). RYUHX has a lower initial minimum investment than USPIX: RYUHX (2500) vs USPIX (15000). RYUHX annual gain was more profitable for investors over the last year : -15.75 vs. USPIX (-39.40). RYUHX return over 5 years is better than : -52.03 vs. USPIX (-93.32).
RYUHXUSPIXRYUHX / USPIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence10 years27 years-
Gain YTD-15.614-39.20640%
Front LoadN/AN/A-
Min. Initial Investment25001500017%
Min. Initial Investment IRAN/A15000-
Net Assets31.7M9.32M340%
Annual Yield % from dividends3.326.9048%
Returns for 1 year-15.75-39.4040%
Returns for 3 years-16.32-57.9028%
Returns for 5 years-52.03-93.3256%
Returns for 10 years-73.22-98.9874%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EKSO0.61N/A
+0.83%
Ekso Bionics Holdings
APLE15.710.10
+0.64%
Apple Hospitality REIT
TEF4.040.01
+0.25%
Telefonica SA
DSX1.88-0.03
-1.57%
Diana Shipping
GYRE11.90-0.30
-2.46%
Gyre Therapeutics